We have used the yeast two-hybrid system to identify proteins that interact with the intracellular portion of the hepatocyte growth factor (HGF) receptor (Met). We isolated a human cDNA encoding a novel protein of 68 kDa, which we termed FAP68. This protein is homologous to a previously described FK506-binding protein-associated protein, FAP48, which derives from an alternative spliced form of the same cDNA, lacking an 85-nucleotide exon and leading to an early stop codon. Here we show that epithelial cells, in which the HGF receptor is naturally expressed, contain FAP68 and not FAP48 proteins. FAP68 binding to Met requires the last 30 amino acids of the C-terminal tail, which are unique to the HGF receptor. Indeed, FAP68 does not interact with related tyrosine kinases of the Met and insulin receptor families. FAP68 interacts specifically with the inactive form of HGF receptor, such as a kinase-defective receptor or a dephosphorylated wild type receptor. In vivo, endogenous FAP68 can be coimmunoprecipitated with the HGF receptor in the absence of stimuli and not upon HGF stimulation. Thus, FAP68 represents a novel type of effector that interacts with the inactive HGF receptor and is released upon receptor phosphorylation. Free FAP68 exerts a specific stimulatory activity toward the downstream target p70 S6 protein kinase (p70S6K). Significantly, nonphosphorylated HGF receptor prevents FAP68 from stimulating p70S6K. These data suggest a role for FAP68 in coupling HGF receptor signaling to the p70S6K pathway.

Hepatocyte growth factor (HGF) is a cytokine controlling proliferation and cell-cell dissociation ("scattering") in a broad spectrum of cells. It also induces formation of tubular structures in epithelial and endothelial cells and axon sprouting in neurons (for a review, see Ref. 1 and references within). The HGF receptor is the transmembrane tyrosine kinase encoded by the c-MET proto-oncogene, which has been genetically linked with human cancer (2). The downstream signaling cascades linking the ligand-activated receptor to the control of cell proliferation, scattering, and differentiation have been carefully analyzed. The three biological responses are triggered by phosphorylation of a unique multifunctional docking site containing two tyrosines (Tyr\textsuperscript{1349} and Tyr\textsuperscript{1356}), located in the receptor C-terminal tail (3, 4). The two photophysosines interact with multiple cytoplasmic signal transducers either directly, or indirectly, via molecular adaptors such as Grb2 (5), She (6), and Gab-1 (7). After HGF stimulation, the receptor binds and activates phosphatidylinositol 3-kinase (PI3K; Refs. 8 and 9) and Src (3), recruits the Grb2/Sos complex stimulating Ras (10), and directly phosphorylates the transcriptional factor Stat-3 (11). The Gab-1 adaptor recruits additional signal transducers, such as PI3K, phospholipase C-\(\gamma\), and the SHP2 phosphatase, and activates the Rac-c-Jun N-terminal kinase signaling pathway through the bound Crk adaptor (for a review, see Ref. 12 and references within). The use of dominant negative proteins and selective inhibitors indicates that PI3K, Rac, and Src activations are responsible for scattering (13–15); the Ras pathway is responsible for cell proliferation (5); and Stat-3, phospholipase C-\(\gamma\), and SHP2 pathways are required for induction of branching morphogenesis (11, 16, 17). The complex, pleiotropic effects of HGF suggest that there may be additional signal transducers and effectors still to be discovered.

In this study we performed a genetic screen with the yeast two-hybrid system to identify novel proteins capable of associating with the unstimulated HGF receptor. We cloned a cDNA coding for a 68-kDa cytoplasmic protein, FAP68, which is specifically bound by the nonphosphorylated form of the HGF receptor and is released upon HGF stimulation and receptor phosphorylation. We provide evidence that forced expression of FAP68 in epithelial cells induces phosphorylation of p70S6K, without affecting the MAPK pathway. Co-transfection of nonphosphorylated HGF receptor prevents FAP68 from stimulating p70S6K. These findings suggest a potential role for FAP68 in linking HGF signaling to the regulation of protein synthesis.

**EXPERIMENTAL PROCEDURES**

**Interaction Trap Screening of HeLa cDNA Library**—To perform a yeast interaction trap screening (18), the cDNA encoding for the HGF receptor intracellular domain carrying a mutation in the ATP-binding site (Lys\textsuperscript{1110} to Ala) was generated by PCR from the corresponding full-length construct in pMT2 vector (19). The PCR product was sequenced and inserted in pEG202 vector, fused to the LexA DNA-binding (IC-KD bait). The *Saccharomyces cerevisiae* strain EGY48 was co-transformed with the bait and the lacZ reporter pSH18–34. Yeast cells were then transformed with a HeLa cDNA library (from Roger Brent) in
vector pG4–5 using the lithium acetate method (20). Over 2 million transformants were obtained and screened. Among the 700 yeast colonies isolated as Leu-positive, 35 were found to display both leucine prototrophy and lacZ expression only upon specific induction of the library expression with galactose. Plasmid DNA was rescued from these colonies in medium-dense transformants three times. The C-terminus of the GST fusion construct was connected to the IC-KD bait or with unrelated bait, pEG202-bicoid. Fourteen clones remained specifically positive. From restriction mapping it appeared that four groups of cDNAs, encoding distinct proteins, had been isolated (to be described elsewhere). The cDNA inserts from specific clones were sequenced using the ABI Prism 3001 Genetic Analyzer (PerkinElmer Life Sciences). Clone T291, which is the only clone with three other independent clones, was selected for the present study.

**RACE Analysis**—To obtain the 5' sequence of clone T291, 5'-RACE-PCR on HeLa Marathon-Ready DNA (CLONTECH) was performed, using as gene-specific primer an oligonucleotide annealing inside the 85-bp sequence present in FAP68 but absent in FAP45 (5'-GCTCGGCACACCTGAGTGATTACTTG-3'). Of the 17 5' cDNAs that were retrieved, the 4 longest started at nucleotide 12 of the published cDNA (CLONTECH) was performed, and cDNAs that were retrieved, the 4 longest started at nucleotide 12 of the published cDNA (CLONTECH) was performed, and cDNAs that were retrieved, the 4 longest started at nucleotide 12 of the published FAP68 sequence (GenBank accession no. U73704), and were identical to it. We performed a 3'-RACE-PCR using as gene-specific primer an oligonucleotide annealing within the 5'-untranslated region (5'-GAGGTTTCTGGCCTGGATT ATTACTTG-3'). All 20 3' cDNAs that were retrieved had the same size and contained the 85-bp sequence.

**Expression Vectors and Constructs**—Various HGF receptor genes were generated by PCR from a human full-length Met (21) and were fused to the LexA DNA binding domain in pEG202 vector (see the list in Fig. 2). The intracellular constructs of Ron (aa 983–1400 of either wild type or carrying the ATP binding site mutation) were generated by PCR from a human full-length Ron (22) and were fused to the LexA DNA binding domain in pEG202 vector. pEG202 and pEG202 containing the bicoid and pG4–5 plasmids were provided by Dr. W. Kolanus. pEG202 containing the IGF-1R and insulin receptor (wild type or carrying the ATP binding site mutation) were obtained from Dr. T. A. Gustafson. The GST-fused intracellular domain of wild type HGF receptor cDNA cloned into baculovirus vector has been described previously (22). This domain was either fused to the LexA DNA binding domain as described previously (23). For transient transfection experiments, the FAP68 3'-RACE cDNA was inserted in pc2R1-1 TOPO vector (Invitrogen) and sequenced. The FAP68- VS VG and the FAP68-GST were PCR-amplified from FAP68 3'-RACE cDNA, sequenced, and cloned in frame in pEG202 vector. The GST-fused intracellular domain of wild type HGF receptor cDNA cloned into baculovirus vector has been described previously (23). For transient transfection experiments, the FAP68 3'-RACE cDNA was inserted in pc2R1-1 TOPO vector (Invitrogen) and sequenced. The FAP68-VSVG and the FAP68-GST were PCR-amplified from FAP68 3'-RACE cDNA, sequenced, and cloned in frame in pcDNA3 vector with a modified VSVG peptide epitope (21) and were fused to the LexA DNA binding domain in pEG202 vector (see the list in Fig. 2). The intracellular constructs of Ron (aa 983–1400 of either wild type or carrying the ATP binding site mutation) were generated by PCR from a human full-length Ron (22) and were fused to the LexA DNA binding domain in pEG202 vector. pEG202 and pEG202 containing the bicoid and pG4–5 plasmids were provided by Dr. W. Kolanus. The GST-fused intracellular domain of wild type HGF receptor cDNA cloned into baculovirus vector has been described previously (22). This domain was either fused to the LexA DNA binding domain as described previously (23). For transient transfection experiments, the FAP68 3'-RACE cDNA was inserted in pc2R1-1 TOPO vector (Invitrogen) and sequenced. The FAP68-VSVG and the FAP68-GST were PCR-amplified from FAP68 3'-RACE cDNA, sequenced, and cloned in frame in pcDNA3 vector with a modified VSVG peptide epitope (21) and were fused to the LexA DNA binding domain in pEG202 vector. pEG202 and pEG202 containing the bicoid and pG4–5 plasmids were provided by Dr. W. Kolanus. The GST-fused intracellular domain of wild type HGF receptor cDNA cloned into baculovirus vector has been described previously (22). This domain was either fused to the LexA DNA binding domain as described previously (23). For transient transfection experiments, the FAP68 3'-RACE cDNA was inserted in pc2R1-1 TOPO vector (Invitrogen) and sequenced. The FAP68-VSVG and the FAP68-GST were PCR-amplified from FAP68 3'-RACE cDNA, sequenced, and cloned in frame in pcDNA3 vector with a modified VSVG peptide epitope (21) and were fused to the LexA DNA binding domain in pEG202 vector. pEG202 and pEG202 containing the bicoid and pG4–5 plasmids were provided by Dr. W. Kolanus. The GST-fused intracellular domain of wild type HGF receptor cDNA cloned into baculovirus vector has been described previously (22). This domain was either fused to the LexA DNA binding domain as described previously (23). For transient transfection experiments, the FAP68 3'-RACE cDNA was inserted in pc2R1-1 TOPO vector (Invitrogen) and sequenced. 

**RESULTS**

**Interaction Trap Cloning of FAP68**—To identify target proteins that interact with the intracellular portion of the HGF receptor, we used the yeast Interact Trap System (18). Because there are already many known Src homology 2 or phosphotyrosine B transducers that bind the tyrosine-phosphorylated HGF receptor, we screened for proteins that recognize the nonphosphorylated intracellular domain. To this aim a bait was produced by fusing the LexA DNA-binding domain with a cDNA encoding the cytoplasmic portion of the receptor, carrying the Lys311→ Ala inactivating mutation in the ATP-binding site (IC-KD bait; see Fig. 2A). This mutation is sufficient to completely switch off the tyrosine kinase activity of the receptor.

Over 2 million cDNA clones from a HeLa cDNA expression library were screened; of the 700 yeast colonies selected, 14 were positive after two rounds of transformation. From restriction maps it appeared that four groups of cDNA encoding distinct proteins had been isolated. The complete sequencing of clone T291 and comparison with the GenBank nucleotide data base using BLAST showed that T291 is homologous to a pre-
FKBP-associated protein 48; GenBank/H23042
pressed in cells, a polyclonal antibody was raised against a
FAP48 was found.

GenBank, contains the
ited at the High Throughput Genomic Sequences division of
, is identical to /H23042 GenBank (GenBank tags contain the 85-bp sequence and the single base pair dele-
therefore named ). It was
cleotides, which encodes a protein of 594 amino acid residues,
from HeLa cells, includes an open reading frame of 1785 nu-
ppeptide sequence encompassing aa 194–212, common to FAP68 and
peptide encompassing aa 194–212, common to FAP68 and
FAP48. In an immunoblot of a panel of epithelial cell lines, the
immune serum recognized a major band migrating in SDS-
PAGE as a closely spaced doublet of ~65 kDa (Fig. 1B).

Interaction between FAP68 and HGF Receptor—The interaction
between FAP68 protein and HGF receptor was further studied by co-transforming yeast with clone T291 (aa 25–594)
and various receptor mutants (Fig. 2A). A bait containing the
intracellular portion of wild type HGF receptor constitutively
phosphorylated on tyrosine (IC bait, Fig. 2B) failed to interact
with clone T291 (Fig. 2C). This indicates that binding is
prevented by tyrosine phosphorylation of the receptor. Two dele-
tion mutants were derived from the kinase-defective receptor
used in the original screening (IC-KD bait): TKC lacking the
juxtamembrane domain, and JTK lacking the C-terminal tail
(Fig. 2A). Of these, only TKC interacted with clone T291 (Fig.
2C), thus indicating that binding requires the C-terminal tail.
Indeed, the last 57 amino acids of the receptor (C57 bait)
showed a positive interaction, although weaker than that
detected in the presence of the catalytic domain. The C-terminal
tail containing the two tyrosines Tyr1349 and Tyr1356 of the
multifunctional docking site but devoid of last 30 amino acids
(C27 bait) failed to interact with clone T291. This indicates that
the last 30 amino acids of the C-terminal tail are required for
binding.

On the FAP68 side, we generated various deletion mutants
and found that the intact molecule is required for specific
binding to the receptor, except for the first 25 amino acids,
which are dispensable (data not shown). The specificity of the
interaction was assessed by testing baits containing the cyto-
plasmic domain of Ron, a Met subfamily member, and two
related tyrosine kinases, the IGF-1R and the insulin receptor.
Neither wild type nor kinase-defective receptors (carrying a
mutated ATP binding site) did bind FAP68 (data not shown).

The interaction between FAP68 and HGF receptor was
investigated in mammalian cells in vivo (Fig. 3). As observed in
yeast, in co-transfected COS-7 cells, GST-tagged FAP68 interact-
acted with the kinase-defective but not with the kinase-active
wild type HGF receptor (Fig. 3A), which in COS-7 cells is
autophosphorylated as consequence of overexpression (27).
Identical results were obtained when TprMet was used (Fig.
3B). TprMet is a hybrid molecule, encoded by the
TPR-MET transforming gene (28); the extracellular domain of Met recept-
or is replaced by Tpr sequences, which provide two strong
dimerization motifs (29), followed by the Met kinase domain
and C-terminal tail. In the TprMet15 mutant, the two critical
tyrosines of the multifunctional docking site (corresponding to
the Tyr1349/Tyr1356 in the full-size receptor) were converted
into phenylalanine (3). This Tyr → Phe conversion abrogates
signaling, but does not affect the TprMet5 catalytic activity and
constitutive phosphorylation of other sites. Neither TprMet1
nor TprMetWT were able to bind FAP68-GST (Fig. 3B). This
result suggests that the phosphorylated HGF receptor cannot
bind FAP68 because of structural changes in the C-terminal
tail rather than steric blockade by phosphotyrosine residues of
the multifunctional docking site.

The interaction between FAP68 and nonphosphorylated wild
type HGF receptor was confirmed in vitro, using purified mol-
ecules. The intracellular domain of wild type HGF receptor,
purified from baculovirus-infected cell lysates and constitut-
ively phosphorylated (GST-phospho-IC), did not interact with
in vitro translated and radiolabeled FAP68 (Fig. 4). However,
dephosphorylation by phosphatase treatment, GST-
dephospho-IC acquired the ability of binding FAP68. This con-
irms that FAP68 binding is specific for the nonphosphorylated
HGF receptor and that the interaction of the kinase-defective

Fig. 1. Primary sequence and biochemical structure of FAP68
protein. A, the amino acid sequence was predicted from the sequence
of a full-length cDNA obtained by RACE-PCR from HeLa mRNA. The
cDNA includes an open reading frame of 1785 nucleotides and encodes a
protein of 594 amino acid residues, with a predicted molecular mass
of 68,204 kDa. B, a polyclonal antibody (a-FAP), directed against a
peptide sequence encompassing aa 194–212, common to FAP68 and
FAP48, recognizes a major endogenous protein resolved by 10% SDS-
PAGE as a doublet of ~65 kDa in Western blot analysis.

A

B

| Total lysates | Blot o- FAP |
|--------------|------------|
| 1: AD48      |            |
| 2: C8B-7     |            |
| 3: NT29      |            |
| 4: HEPG2     |            |
| 5: SKBR3     |            |
| 6: HeLa      |            |

Downloaded from http://www.jbc.org/ by guest on July 26, 2018
mutant is not the result of the introduced mutation in the ATP-binding site.

**HGF Stimulation Causes Release of Tyrosine-phosphorylated FAP68 in Vivo**

To determine, under physiological conditions, whether the association between FAP68 and the HGF receptor depends on receptor phosphorylation, we examined the interaction between the two endogenous proteins in serum-starved and HGF-stimulated HEK-293 cells. The HGF receptor was immunoprecipitated with DO24 monoclonal antibody directed against the receptor extracellular domain. This antibody preferentially reacts with the phosphorylated Met receptor (30). The immune complex was analyzed by immunoblotting with α-FAP polyclonal antiserum. Coimmunoprecipitation of FAP68 was observed with the nonphosphorylated HGF receptor but was no longer detected in the immune complex after HGF stimulation (Fig. 5A). We then investigated whether FAP68 was phosphorylated upon HGF receptor activation. FAP68 was immunoprecipitated with α-FAP antiserum from serum-starved and HGF-stimulated HEK293 cells. The immune complex was analyzed by immunoblotting with α-FAP and α-phosphotyrosine antibodies. We found that following HGF stimulation a fraction of FAP68 protein underwent a gel migration shift and became tyrosine-phosphorylated (Fig. 5B). This indicates that in vivo FAP68 released from the receptor upon HGF receptor activation is tyrosine-phosphorylated.

**FAP68 Increases the Phosphorylation of p70S6K**

We then...
target of PI3K, and on MAPK, a downstream target of Ras. HEK-293 cells were co-transfected with p70S6K-Glu and FAP68, or p70S6K and empty vector as a control, serum-starved for 16 h, and analyzed for basal p70S6K activity. In vivo, p70S6K activity is closely related to the state of phosphorylation of Thr$^{412}$ (30, 31). Using specific antibodies against the phosphorylated form of Thr$^{412}$, we observed that co-expression of FAP68 with p70S6K stimulated phosphorylation of Thr$^{412}$ (Fig. 6A). The stimulation was comparable with that induced by addition of fetal calf serum to control cells. The effect of FAP68 was specific, as co-expression of ezrin did not result in increased p70S6K phosphorylation (data not shown). The same type of analysis was performed on endogenous p70S6K in HEK-293 cells overexpressing FAP68 and GFP. In experiments where the transfection efficiency was close to 90%, Thr$^{412}$ phosphorylation and a shift of p70S6K were clearly detectable with the appropriate antibodies (Fig. 6B). We then examined the effect of FAP68 on p44 MAPK. Co-transfection with FAP68 failed to activate MAPK, as assessed by immunoblot with specific antibodies against the phosphorylated form of MAPK (Fig. 6C). These results indicate that FAP68 does not have a general activating effect on cellular kinases but rather specifically stimulates p70S6K phosphorylation.

**A Mechanism Coupling HGF Receptor and p70S6K Activity.** We consequently asked whether the stimulatory activity of FAP68 toward p70S6K could be regulated by the interaction between FAP68 and the HGF receptor. FAP68 (or empty vector as a control), p70S6K, and the kinase-defective mutant TprMet$^{KD}$ were co-expressed in HEK-293 cells, and p70S6K phosphorylation was detected by immunoblotting with specific antibodies against the phosphorylated form of Thr$^{412}$. The ability of FAP68 to increase the level of the p70S6K phosphorylation was abrogated in the presence of the kinase-defective TprMet mutant (Fig. 7). Wild type TprMet is inappropriate as
FAP68 Interaction with HGF Receptor

FIG. 7. Nonphosphorylated HGF receptor prevents FAP68 stimulatory activity toward p70S6K. A HeK293 cell line co-transfected with p70S6K-Glu (2.5 μg) and FAP68-VSVG or p70S6K-Glu and empty vector as a control, in combination with either TprMetKD (kinase-defective) or TprMetKD (Tyr1349/Tyr1356 → Phe double mutant). Cells were starved for 16 h in serum-free medium and lysed. Stimulation of p70S6K was detected by immunoblotting of total lysates with a phopho-specific antibody (upper two panels). The expression of transfected proteins was assayed by immunoblotting of total lysates with α-Glu, α-Met, and α-VSVG antibodies. Vsg, VSVG.

a control for this experiment, because it can enhance the p70S6K by stimulation of the PI3K pathway. We thus used the TprMetKD mutant, unable to signal through the tyrosines Tyr1349/Tyr1356 of the multifunctional docking site, mutated into phenylalanines. TprMetKD did not bind FAP68 (see Fig. 3E) and did not interfere with the up-regulation of p70S6K activation induced by FAP68.

DISCUSSION

In this paper we have identified by interaction screening a novel protein of 68 kDa (FAP68), which specifically interacts with the HGF receptor. A splice variant, FAP48, was previously found by two-hybrid screening using FKBP52 protein as a bait (26). Our data indicate that this lower molecular mass form results from an off-frame truncation of the FAP68 transcript. Using antibodies against common peptides, we have shown that FAP68 is widely distributed in human epithelial cells, whereas FAP48 is undetectable. The high level of expression of FAP68 in epithelial cells, where HGF receptor is predominantly found, supports the idea that it may function in HGF signaling.

The interaction between FAP68 and the HGF receptor is direct and occurs with the nonphosphorylated receptor. More than one region of FAP68 is likely to contribute to formation of the receptor-binding site, because the cleavage of the molecule into two halves abrogates binding. The last 57 amino acids of the HGF receptor C-terminal tail contain a minimal binding site for FAP68, and the last 30 amino acids are an essential component of this site. This region of 30 residues in the C-terminal tail diverges even among members of the Met receptor family, suggesting that FAP68 binding may be a unique property of the HGF receptor. The sequence recognized by FAP68 is next to the region of the Met multifunctional docking site, involved in binding the Src homology 2- and phosphotyrosine B-containing effectors (3). Receptor phosphorylation inhibits FAP68 binding. This is not caused by steric hindrance of the phosphorylated tail residues Tyr1349 and Tyr1356, as a mutant lacking these two tyrosines but still kinase-active (TprMetKD) does not bind FAP68. Rather, conformational changes in the C-terminal tail of the receptor following activation are likely to inhibit binding and to induce release of FAP68. Interestingly, upon ligand-induced receptor activation, FAP68 becomes tyrosine-phosphorylated. This modification, in addition to changes in Met structure, may contribute to the release of FAP68.

Release of FAP68 may expose a site on the receptor to which another effector may bind. In this case FAP68 may serve as an inhibitor of signaling prior to receptor activation. This is an attractive hypothesis, considering that the HGF receptor C-terminal tail is the organizing center for the assembly of large signaling complexes proximal to the receptor. Alternatively, the regulated release may serve to allow FAP68 to move to its site of action. A number of signaling mechanisms dependent on phosphorylation-induced release have been described. An example is the activation of the Stat pathway. Here, the phosphorylated receptor recruits the Src homology 2-containing transcription factor to the membrane and phosphorylates it, inducing dimerization and release into the cytoplasm. Then, the dimer migrates to the nucleus and activates transcription (32). Another example is activation of Smad transcription factors, which are released from the transforming growth factor-β family receptors upon phosphorylation on serine residues and translocated into the nucleus where they induce transcription (33). Some cytoplasmic molecules have been shown to specifically interact with nonphosphorylated tyrosine kinase receptors. For instance, a cell cycle checkpoint regulatory protein, MAD2, is released from the insulin receptor after activation (34) and a zinc finger protein selectively binds the unstimulated epidermal growth factor receptor and translocates to the nucleus upon release from the activated receptor (35).

The important question that remains open is the real function of FAP68 and its role in HGF signaling. Very little is known of this protein. It has no substantial similarities with already known sequences, except for the FAP48 isoform. It shares with FAP48 (26) the ability to associate with the FKBP proteins, the targets of immunosuppressant drugs FK506 and rapamycin, using a putative rapamycin/FK506 mimetic structure (data not shown). This raises the possibility that FAP48 and/or FAP68 act in the signal transduction pathways targeted by FK506 and/or rapamycin.

Here we show that FAP68 exerts a specific effect on p70S6K. The detailed biochemical mechanisms by which FAP68 up-regulates p70S6K are presently unclear. Regardless of the mechanism, FAP68 binding with the nonphosphorylated HGF receptor prevents its stimulatory activity toward p70S6K.

Activation of p70S6K is essential for HGF-induced hepatocyte proliferation (40). Met can activate p70S6K via PI3K (8). Our data suggest that the release of FAP68 from the activated receptor may synergize with PI3K to reinforce HGF-induced p70S6K signaling (13). This occurs via phosphorylation of Thr112, which is controlled by upstream kinase(s) (37) and by serine/threonine phosphatase(s) inhibited by the mammalian target of rapamycin TOR (38, 39). An intriguing idea could be that FAP68 may participate in the cellular regulation of mammalian TOR. Work is in progress to investigate whether FAP68 is functionally linked with TOR or is involved in different aspects of HGF signaling.

Acknowledgments—We are grateful to Dr. Waldemar Kolanus and the Munich Genzentrum for helpful introduction to the interaction trap system. We gratefully acknowledge R. Albano, G. Petruccelli, and L. Palmas for technical assistance, and M. Battaglia and S. Perga for technical assistance, and M. Battaglia and S. Perga for technical assistance, and M. Battaglia and S. Perga for technical assistance, and M. Battaglia and S. Perga for technical assistance, and M. Battaglia and S. Perga for technical assistance. We gratefully acknowledge R. Albano, G. Petruccelli, and L. Palmas for technical assistance, and M. Battaglia and S. Perga for help in some of the experiments. We thank Dr. S. Giordano and Dr. P. Gual for advice, encouragement, and lively discussion, and Professor C. Ponzetto for useful comments and critical reading of the manuscript. We are pleased to acknowledge the seminal work of Professor E. E. Baulieu in this topic.

REFERENCES

1. Tamagnone, L., and Comoglio, P. M. (1997) Cytokine Growth Factor Rev. 8, 129–142
2. Schmidt, L., Duh, F. M., Chen, F., Kishida, T., Glenn, G., Choyke, P., Scherer, S. W., Zhuang, Z., Lubensky, I., Dean, M., Allikmets, R., Chidambaram, A., Bergerheim, U. R., Felits, J. T., Casadevall, C., et al. (1997) Nat. Genet. 16, 68–73.
3. Ponzetto, C., Bardelli, A., Zhen, Z., Maina, F., Dalla Zonca, Giordano, S., Graziani, A., Panayotou, G., and Comoglio, P. M. (1997) Cell 77, 261–271
4. Sachs, M., Weidner, K. M., Brinkmann, V., Walther, I., Obermeier, A., Ullrich, A., and Birchmeier, W. (1996) J. Cell Biol. 138, 1095–1107
FAP68 Interaction with HGF Receptor

5. Ponzetto, C., Zhen, Z., Audero, E., Maina, F., Bardelli, A., Basile, M. L., Giordano, S., Narsimhan, R., and Comoglio, P. (1996) J. Biol. Chem. 271, 11421–11423
6. Pelicci, G., Giordano, S., Zhen, Z., Salcini, A. E., Lanfrancone, L., Bardelli, A., Panayotou, G., Waterfield, M. D., Ponzetto, C., and Pelicci, P. G. (1995) Oncogene 10, 1631–1638
7. Weidner, K. M., DiCesare, S., Sachs, M., Brinkmann, V., Behrens, J., and Birchmeier, W. (1996) Nature 384, 173–176
8. Graziani, A., Gramaglia, D., Dalla Zonca., P., and Comoglio, P. M. (1993) J. Biol. Chem. 268, 14900–14907
9. Graziani, A., Giordano, S., Narsimhan, R., and Comoglio, P. (1996) J. Biol. Chem. 271, 15152–15160
10. Graziani, A., Audero, E., Maina, F., Longati, P., Panayotou, G., Dhand, R., Waterfield, M. D., and Comoglio, P. M. (1993) Mol. Cell. Biol. 13, 4600–4608
11. Boccaccio, C., Ando, M., Tamagnone, L., Bardelli, A., Michieli, P., Battistini, C., and Comoglio, P. M. (1998) Nature 391, 285–288
12. Purge, K. A., Zhang, Y. W., and Vande, Woude, G. F. (2000) Oncogene 19, 5582–5589
13. Ridley, A. J., Comoglio, P. M., and Hall, A. (1995) Mol. Cell. Biol. 15, 1110–1122
14. Rahimi, N., Hung, W., Tremlay, E., Saulnier, R., and Elliott, B. (1996) J. Biol. Chem. 273, 33714–33721
15. Gietz, D., St, Woods, R. A., and Schiestl, R. H. (1992) EMBO J. 11, 2859–2866
16. Gual, P., Giordano, S., Williams, T. A., Rocchi, S., Van Obberghen, E., and Comoglio, P. M. (2000) Oncogene 19, 1509–1518
17. Schaeper, U., Gehring, N. H., Puchs, K. F., Sachs, M., Kempkes, B., and Birchmeier, W. (2000) J. Cell Biol. 149, 1419–1432
18. Goelz, S. M., Smolik, J., and Brent, R. (1995) in Current Protocols in Molecular Biology (Ausubel, F. A., et al., eds) pp. 20.1.1–20.1.28, John Wiley & Sons, New York.
19. Crepaldi, T., Prat, M., Giordano, S., Medico, E., and Comoglio, P. M. (1994) J. Biol. Chem. 269, 1750–1755
20. Gietz, D., St, Woods, R. A., and Schiestl, R. H. (1992) Nucleic Acids Res. 20, 1425–1430
21. Gaudino, G., Panayotou, G., and Comoglio, P. M. (1998) Proc. Natl. Acad. Sci. U. S. A. 96, 469–473
22. Follenzi, A., Bakovic, S., Gual, P., Stella, M. C., Longati, P., and Comoglio, P. M. (2000) Oncogene 19, 3041–3049
23. Bardelli, A., Longati, P., Albero, D., Goruppi, G., Schneider, C., Ponzetto, C., and Comoglio, P. M. (1996) EMBO J. 15, 6205–6212
24. Naldini, L., Vigna, E., Bardelli, A., Follenzi, A., Galimi, F., and Comoglio, P. M. (1995) J. Biol. Chem. 270, 603–611
25. Prat, M., Crepaldi, T., Pennacchietti, S., Bussolino, F., and Comoglio, P. M. (1998) J. Cell Sci. 111, 237–247
26. Chambraud, B., Radanyi, C., Camonis, J. H., Shazand, K., Rajkowski, K., and Baulieu, E. E. (1996) J. Biol. Chem. 271, 32923–32929
27. Bardelli, A., Maina, F., Gout, I., Fry, M. J., Waterfield, M. D., Comoglio, P. M., and Ponzetto, C. (1992) Oncogene 7, 1973–1978
28. Cooper, C. S., Park, M., Blair, D. G., Tainsky, M. A., Huebner, K., Croce, C. M., and Vande, W. (1984) Nature 311, 29–33
29. Rodrigues, G. A., and Park, M. (1995) Mol. Cell. Biol. 15, 6711–6722
30. Dennis, P. B., Pullen, N., Pearson, R. B., Kozma, S. C., and Thomas, G. (1998) J. Biol. Chem. 273, 14845–14852
31. Weng, Q. P., Kozlowski, M., Belham, C., Zhang, A., Comb, M. J., and Avruch, J. (1998) J. Biol. Chem. 273, 16621–16629
32. Karin, M., and Hunter, T. (1995) Curr. Biol. 5, 747–757
33. Massague, J., and Wotton, D. (2000) EMBO J. 19, 1745–1754
34. O’Neill, T. J., Zhu, Y., and Gustafson, T. A. (1996) J. Biol. Chem. 272, 10040–10049
35. Galcheva-Gargova, Z., Konstantinov, K. N., Wu, I. H., Klier, F. G., Barrett, T., and Davis, R. J. (1996) Science 272, 1797–1802
36. Peterson, R. T., and Schreiber, S. L. (1999) Curr. Biol. 9, R521-R524
37. Thomas, G., and Hall, M. N. (1997) Curr. Opin. Cell Biol. 9, 782–787
38. Peterson, R. T., Beal, P. A., Comb, M. J., and Schreiber, S. L. (2000) J. Biol. Chem. 275, 7416–7423
39. Kimura, M., and Ogihara, M. (1997) J. Pharmacol. Exp. Ther. 282, 1146–1154
Ligand-regulated Binding of FAP68 to the Hepatocyte Growth Factor Receptor
Silvia Grisendi, Beatrice Chambraud, Ivan Gout, Paolo M. Comoglio and Tiziana Crepaldi

J. Biol. Chem. 2001, 276:46632-46638.
doi: 10.1074/jbc.M104323200 originally published online September 24, 2001

Access the most updated version of this article at doi: 10.1074/jbc.M104323200

Alerts:
- When this article is cited
- When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

This article cites 38 references, 22 of which can be accessed free at
http://www.jbc.org/content/276/49/46632.full.html#ref-list-1